PDT Partners LLC Purchases 66,647 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

PDT Partners LLC raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 382.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 84,062 shares of the biopharmaceutical company's stock after buying an additional 66,647 shares during the period. PDT Partners LLC owned about 0.07% of Halozyme Therapeutics worth $4,019,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of HALO. Vanguard Group Inc. boosted its position in Halozyme Therapeutics by 3.0% during the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after purchasing an additional 386,618 shares during the last quarter. Snyder Capital Management L P raised its stake in shares of Halozyme Therapeutics by 2.6% during the 4th quarter. Snyder Capital Management L P now owns 4,168,453 shares of the biopharmaceutical company's stock worth $199,294,000 after purchasing an additional 105,086 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Halozyme Therapeutics by 2.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company's stock valued at $92,446,000 after buying an additional 47,795 shares during the last quarter. Northern Trust Corp grew its stake in shares of Halozyme Therapeutics by 8.7% in the 4th quarter. Northern Trust Corp now owns 1,827,771 shares of the biopharmaceutical company's stock valued at $87,386,000 after buying an additional 145,617 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Halozyme Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock worth $85,254,000 after buying an additional 9,780 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Performance

NASDAQ HALO traded up $1.16 during trading on Friday, hitting $61.19. The company's stock had a trading volume of 1,098,414 shares, compared to its average volume of 1,441,583. Halozyme Therapeutics, Inc. has a 52 week low of $39.79 and a 52 week high of $66.00. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The firm has a market cap of $7.56 billion, a P/E ratio of 17.84, a price-to-earnings-growth ratio of 0.42 and a beta of 1.26. The firm has a 50 day moving average price of $60.79 and a 200 day moving average price of $55.37.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last issued its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

HALO has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. HC Wainwright restated a "buy" rating and set a $72.00 target price on shares of Halozyme Therapeutics in a report on Friday, April 25th. Benchmark reiterated a "buy" rating and set a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, Wells Fargo & Company cut their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $62.89.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total transaction of $580,500.00. Following the completion of the transaction, the senior vice president now owns 185,453 shares in the company, valued at $10,765,546.65. This trade represents a 5.12 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jeffrey William Henderson sold 4,497 shares of the company's stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $60.37, for a total value of $271,483.89. Following the completion of the sale, the director now owns 28,611 shares in the company, valued at approximately $1,727,246.07. This represents a 13.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,697 shares of company stock valued at $1,558,052 in the last quarter. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.